The effectiveness of early administration of interleukin-17 blockers in the treatment of axial lesions in psoriatic arthritis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Currently, studies on evaluation of the effectiveness of netakimab not only in psoriasis and psoriatic arthritis, but also in axial spondy-loarthritis are underway. Research results confirm the effectiveness of the drug in enthesitis, dactylitis, axial lesions. In this report, we present the clinical experience of using netakimab in the treatment of severe psoriasis vulgaris, inverse psoriasis and psoriatic onychodystrophy, as well as its effectiveness in the early manifestations of axial lesions of psoriatic arthritis.

Full Text

Restricted Access

About the authors

Larisa S. Kruglova

Central State Medical Academy of Department of Presidential Affairs

Email: kruglovals@mail.ru
Dr. Sci (Med.), Professor, Vice-Rector for Academic Affairs, Head of the Department of Dermatovenereology and Cosmetology

N. O Pereverzina

Central State Medical Academy of Department of Presidential Affairs

References

  1. Ritchiin C.T., Colbert R.A., Giadman D.D. Psoriatic Arthritis. N Engl J Med. 2017;376(10):957-70. doi: 10.1056/NEJMra1505557.
  2. Cohen J.M., Husni M.E., Qureshi A.A., Meroia J.F. Psoriatic arthritis: it's as easy as «PSA». J Am Acad Dermatoi. 2015;72(5):905-6. Doi: 10.1016/]. jaad.2014.12.008.
  3. Queiro R., Beizunegui J., Gonzaiez C., et ai. Ciinicaiiy asymptomatic axial disease in psoriatic spondyloarthropathy. A retrospective study. Ciin Rheumatoi. 2002;21(1):10-3. Doi: 10.1007/ s100670200003.
  4. Biachier M, Canouf-Poitrine F., Dougados M., et ai. Factors associated with radiographic iesions in eariy axial spondyioarthritis. Resuits from the DESIR cohort. Rheumatoi. (Oxford). 2013;52(9):1686-93. doi: 10.1093/rheumatoiogy/ket207.
  5. Kampyiafka E., Simon D., d'Oiiveira I., et ai. Disease interception with interieukin-17 inhibition in high-risk psoriasis patients with subciinicai joint infiammation-data from the prospective IVEPSA study. Arthr Res Ther. 2019;21(1):178. doi: 10.1186/s13075-019-1957-0.
  6. McGonagie D.G., Mclnnes I.B., Kirkham B.W., et ai. The roie of IL-17A in axial spondyioarthritis and psoriatic arthritis: recent advances and controversies [published correction appears in Ann Rheum Dis. 2020 Jan;79(1 ):e12. Ann Rheum Dis. 2019;78(9):1167-78. Doi: 10.1136/ annrheumdis-2019-215356.
  7. Абдулганиева Д. И. и др. Раннее назначение генно-инженерных биологических препаратов при иммуновоспалительных заболеваниях: возможности и перспективы. Позиция экспертов. Современная ревматология. 2020; 14:3.
  8. Alinaghi F., Calov M., Kristensen L.E., et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J. Am Acad Dermatol. 2019;80(1):251-265.e19. doi: 10.1016/j.jaad.2018.06.027.
  9. Коротаева Т.В., Мазуров В.И., Лила А.М. и др. Эффективность и безопасность нетакимаба у пациентов с псориатическим артритом: результаты клинического исследования III фазы PATERA. Научно-практическая ревматология. 2020;58(5):480-88.
  10. Erdes S., Nasonov E., Kunder E., et al. Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults. Clin Exp Rheumatol. 2020;38(1):27-34.
  11. Deodhar A., Conaghan PG., Kvien T.K., et al. Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the measure 2 study. Clin Exp Rheumatol. 2019;37(2):260-69.
  12. McInnes I.B., Mease P.J., Schett G., et al. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study. Arthr Res Ther. 2018;7;20(1):113. doi: 10.1186/s13075-018-1610-3.
  13. McInnes I.B., Mease P.J., Ritchlin C.T., et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatol. (Oxford). 2017;56(11):1993-2003. Doi: 10.1093/ rheumatology/kex301.
  14. Kampylafka E., d'Oliveira I., Linz C., et al. Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study. Arthr Res Ther. 2018;20(1):153. doi: 10.1186/s13075-018-1653-5.
  15. Baraliakos X., et al. Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis and Inadequate Response to NSAIDS: Primary Analysis of the MAXIMISE trial PsA and Axial Manifestations. (12 Week Primary Analysis of MAXIMISE) ORAL #OP0235.
  16. Boehncke W.H., Sch n M.P. Psoriasis. Lancet. 2015;386(9997):983-94. Doi: 10.1016/ S0140-6736(14)61909-7.
  17. Круглова Л.С., Львов А.Н., Пушкина А.В. Риски и предикторы псориатического артрита при псориазе и вопросы раннего назначения генно-инженерных биологических препаратов. Клиническая дерматология и косметология. 2020;19(3):289-96.
  18. Yasser E., et al. Knee Enthesitis and Synovitis on Magnetic Resonance Imaging in Patients with Psoriasis without Arthritic Symptoms. J. Rheumatol. 2012;39(10):1979-86. Doi: 10.3899/ jrheum.120301.
  19. Sande N.K., Beyesen P., Aga A.B., et al. Development and reliability of a novel ultrasonographic joint-specific scoring system for synovitis with reference atlas for patients with juvenile idiopathic arthritis. RMD Open. 2021;7(2):e001581. Doi: 10.1136/ rmdopen-2021-001581.
  20. Maldonado-Ficco H., Perez-Alamino R., Maldonado-Cocco J.A. Secukinumab: a promising therapeutic option in spondyloarthritis. Clin Rheumatol. 2016;35(9):2151-61. doi: 10.1007/s10067-016-3350-6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies